2018
DOI: 10.3389/fcvm.2018.00177
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?

Abstract: Evidence for increased risk of cardiovascular morbidity and mortality in chronic inflammatory rheumatic diseases has accumulated during the last years. Traditional cardiovascular risk factors contribute in part to the excess of cardiovascular risk in these patients and several mechanisms, including precocious acceleration of subclinical atherosclerotic damage, inflammation, and immune system deregulation factors, have been demonstrated to strictly interplay in the induction and progression of atherosclerosis. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
14
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 17 publications
(14 citation statements)
references
References 58 publications
0
14
0
Order By: Relevance
“…A number of chronic inflammatory disorders, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and idiopathic inflammatory myopathy, have been strongly linked with atherosclerosis and ischemic heart disease (IHD) in recent decades [9][10][11]. Systemic inflammation has been recognized as a key player in the initiation and progression of atherosclerotic heart disease in patients with chronic autoimmune diseases [10]. Although major vascular involvement is far more common in the disease course of BS, arterial lesions usually manifest as pulmonary arterial aneurysms, whereas coronary artery disease has not been recognized as a prominent feature of BS in earlier clinical studies [12,13].…”
Section: Introductionmentioning
confidence: 99%
“…A number of chronic inflammatory disorders, such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and idiopathic inflammatory myopathy, have been strongly linked with atherosclerosis and ischemic heart disease (IHD) in recent decades [9][10][11]. Systemic inflammation has been recognized as a key player in the initiation and progression of atherosclerotic heart disease in patients with chronic autoimmune diseases [10]. Although major vascular involvement is far more common in the disease course of BS, arterial lesions usually manifest as pulmonary arterial aneurysms, whereas coronary artery disease has not been recognized as a prominent feature of BS in earlier clinical studies [12,13].…”
Section: Introductionmentioning
confidence: 99%
“…The role of antirheumatic drugs in cardiovascular disease prevention has been an intensively researched field in the last decade [ 23 , 24 , 25 ]. Colchicine is the first anti-inflammatory molecule to have been shown in a randomized, double-blind trial to be effective in the secondary prevention of myocardial infarction [ 26 ].…”
Section: Discussionmentioning
confidence: 99%
“…It is also recognized that autoantibodies frequently present in patients with ARDs could interfere with lipid metabolism (16) and endothelial function (17), therefore contributing to the increased CVR in ARDs. However, there is no current consensus regarding the exact mechanism of accelerated atherosclerosis in ARDs (18). This is particularly relevant for people with ARDs with childhood-onset because of the longer disease duration and potential long-life exposure to fluctuating chronic inflammation and other detrimental factors.…”
Section: Autoimmune Rheumatic Diseases (Ards) With Onset In Childhood...mentioning
confidence: 99%